Melinda Gooderham

3 weeks ago | dermatologytimes.com | Emma Andrus |Melinda Gooderham

At the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida, Melinda Gooderham, MD, MSc, FRCPC, a dermatologist and clinical researcher from Peterborough, Ontario, Canada, provided further insights into the safety and systemic exposure profile of delgocitinib cream (LEO Pharma) for chronic hand eczema (CHE).1-2 In part 2 of her interview with Dermatology Times, Gooderham emphasized the importance of safety data, global regulatory approval considerations, and the potential...

3 weeks ago | dermatologytimes.com | Emma Andrus |Melinda Gooderham

At the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida, Melinda Gooderham, MD, MSc, FRCPC, a dermatologist and clinical researcher from Peterborough, Ontario, Canada, presented findings on the systemic exposure of delgocitinib cream (LEO Pharma) under maximal use conditions in chronic hand eczema (CHE).1 The study, presented in a poster titled, "Delgocitinib cream has negligible systemic exposure in patients with maximal use of delgocitinib cream for the treatment of...

Nov 7, 2024 | emjreviews.com | Melinda Gooderham |Marjolein de Bruin-Weller |April W. Armstrong

While for some individuals with atopic dermatitis (AD), the disease can be controlled with topical treatments, those with moderate-to-severe AD often require systemic therapy for long-term disease control. Systemic treatments for AD include conventional systemic agents, small molecule inhibitors, and biologics, each with its own risks and benefits. For example, conventional systemic agents carry significant risks with long-term use, and small molecule inhibitors require frequent dosing.

Sep 28, 2024 | bpno.dk | Melinda Gooderham

september 2024 At EADV 2024, Dr. Melinda Gooderham presented key findings on deucravacitinib, a new oral treatment for psoriasis. Clinical trials (POETYK PSO-1/PSO-2) showed that more than half of patients improved significantly (PASI 75) by week 16, with sustained results for up to four years. The real-world evidence demonstrated significant reductions in psoriasis severity and improved quality of life after six months of treatment.

Sep 27, 2024 | dermatologytimes.com | Kaitlyn Bader |Melinda Gooderham

“It's really great to have 3-year data when a drug is first approved. Normally, when we get a drug approval, the drug is fairly new; we don't have that much long-term efficacy and safety data. With lebrikizumab, we already have at the time of approval, the presentation of 3-year efficacy and safety data,” said Melinda Gooderham, MSc, MD, FRCPC, in an interview with Dermatology Times.